News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision Therapeutics, Inc. Release: Three Abstracts on the ChemoFx® Drug Response Marker Accepted by American Society of Clinical Oncology


5/21/2012 10:27:56 AM

PITTSBURGH--(BUSINESS WIRE)-- Precision Therapeutics announces that the American Society of Clinical Oncology (ASCO) has accepted three individual abstracts that highlight the utility and feasibility of the ChemoFx® Drug Response Marker for patients with gynecologic sarcomas, cervical cancer and ovarian cancer. These abstracts will be published in conjunction with ASCO’s 2012 Annual Symposium, being held June 1-5, 2012 in Chicago, Illinois.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES